Geode Capital Management
STOK icon

Geode Capital Management’s Stoke Therapeutics STOK Stock Holding History

Geode Capital Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.1M Buy
1,322,260
+156,115
+13% +$5.12M ﹤0.01% 1574
2025
Q4 		$37M Buy
1,166,145
+19,145
+2% +$576K ﹤0.01% 1668
2025
Q3 		$27M Buy
1,147,000
+174,079
+18% +$2.98M ﹤0.01% 1845
2025
Q2 		$11M Buy
972,921
+70,935
+8% +$674K ﹤0.01% 2298
2025
Q1 		$6M Buy
901,986
+24,891
+3% +$232K ﹤0.01% 2572
2024
Q4 		$9.68M Buy
877,095
+6,264
+0.7% +$77K ﹤0.01% 2401
2024
Q3 		$10.7M Buy
870,831
+76,661
+10% +$1.09M ﹤0.01% 2337
2024
Q2 		$10.7M Buy
794,170
+154,363
+24% +$2.08M ﹤0.01% 2280
2024
Q1 		$8.64M Buy
639,807
+24,083
+4% +$146K ﹤0.01% 2409
2023
Q4 		$3.24M Buy
615,724
+24,607
+4% +$105K ﹤0.01% 2911
2023
Q3 		$2.33M Sell
591,117
-8,663
-1% -$57K ﹤0.01% 3023
2023
Q2 		$6.38M Buy
599,780
+113,100
+23% +$1.2M ﹤0.01% 2560
2023
Q1 		$4.05M Buy
486,680
+12,456
+3% +$112K ﹤0.01% 2729
2022
Q4 		$4.38M Buy
474,224
+13,969
+3% +$145K ﹤0.01% 2734
2022
Q3 		$5.91M Buy
460,255
+16,446
+4% +$262K ﹤0.01% 2580
2022
Q2 		$5.86M Buy
443,809
+8,038
+2% +$122K ﹤0.01% 2613
2022
Q1 		$9.17M Buy
435,771
+59,617
+16% +$1.19M ﹤0.01% 2405
2021
Q4 		$9.02M Buy
376,154
+12,819
+4% +$306K ﹤0.01% 2517
2021
Q3 		$9.24M Buy
363,335
+7,089
+2% +$198K ﹤0.01% 2501
2021
Q2 		$12M Buy
356,246
+63,210
+22% +$2.23M ﹤0.01% 2334
2021
Q1 		$11.4M Buy
293,036
+21,871
+8% +$1.25M ﹤0.01% 2271
2020
Q4 		$16.8M Buy
271,165
+68,976
+34% +$3.16M ﹤0.01% 1830
2020
Q3 		$6.77M Buy
202,189
+42,245
+26% +$1.21M ﹤0.01% 2211
2020
Q2 		$3.81M Sell
159,944
-25,912
-14% -$615K ﹤0.01% 2495
2020
Q1 		$4.26M Buy
185,856
+66,139
+55% +$1.63M ﹤0.01% 2235
2019
Q4 		$3.39M Buy
119,717
+6,965
+6% +$175K ﹤0.01% 2686
2019
Q3 		$2.42M Buy
+112,752
New +$3.14M ﹤0.01% 2820

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Geode Capital Management's STOK Position: Q1 2026 in Review

Geode Capital Management increased its Stoke Therapeutics (STOK) stake by 13% in Q1 2026, buying an estimated $5.12M and bringing the position to 1,322,260 shares worth $43.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1574.

Geode Capital Management first reported a position in STOK in Q3 2019 and has held it in 27 quarters since. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Geode Capital Management held 1,322,260 shares of Stoke Therapeutics worth $43.1M as of Q1 2026.
  • Geode Capital Management bought 156,115 Stoke Therapeutics shares in Q1 2026, an estimated $5.12M.
  • Stoke Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #1574 holding.
  • Geode Capital Management first reported a position in Stoke Therapeutics in Q3 2019 and has held it in 27 quarters since.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.